
An Automated Platform for Direct-From-Specimen Identification of Pathogens Common in EndocarditisAward last edited on: 1/31/2024
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$4,299,034Award Phase
2Solicitation Topic Code
855Principal Investigator
Alon SingerCompany Information
HelixBind Inc
1300 Massachusetts Avenue Unit 103
Boxborough, MA 01719
Boxborough, MA 01719
(774) 300-8557 |
info@helixbind.com |
www.helixbind.com |
Location: Single
Congr. District: 03
County: Middlesex
Congr. District: 03
County: Middlesex
Phase I
Contract Number: 1R43AI136064-01Start Date: 1/4/2018 Completed: 12/31/2018
Phase I year
2018Phase I Amount
$300,000Public Health Relevance Statement:
PROJECT NARRATIVE Infective Endocarditis (IE) is a serious and life-threatening disease and a significant economic burden due to prolonged intensive treatment. Early microbiological diagnosis is crucial to improving outcomes, but current standards employing blood cultures are lethargic and often yield false-negative results. This delay in crucial information prevents the administration of the evidence-based antimicrobial treatment precisely when it is maximally beneficial. HelixBind will address this problem and develop a novel turn-key approach for early microbiological IE-diagnosis. In this Phase I SBIR, we propose to lay the groundwork for the development of the first fully-automated diagnostic capable of identifying the most prevalent pathogens causing IE, including those difficult or impossible to detect by standard methods, directly from phlebotomy specimens, without prior enrichment, reducing the diagnosis time from days or even weeks to just hours. The information provided would enable the clinician to apply an evidence-driven intervention from the onset of disease symptoms.
Project Terms:
Address; Affect; American; Antibiotics; antimicrobial; assay development; Automation; Bartonella; Benchmarking; Biological Assay; Blinded; Blood; Blood specimen; Blood Volume; Budgets; Capital; Centrifugation; Clinical; Collaborations; Coxiella burnetii; design; Detection; Development; Diagnosis; Diagnostic; diagnostic assay; Disease; DNA; Economic Burden; Endocarditis; Ensure; Etiology; evidence base; experience; Future; General Population; Heart; High Prevalence; Hospitals; Hour; Human; improved; improved outcome; Infection; Infective endocarditis; innovation; instrumentation; Intervention; Invaded; Kinetics; Left; Lethargies; Life; Liquid substance; Medical center; Methods; microbial; Microbiology; molecular diagnostics; Nature; novel; Nucleic Acids; Onset of illness; Organism; Outcome; pathogen; patient population; Patients; Phase; Physicians; Pilot Projects; Populations at Risk; Preparation; prevent; Process; Reagent; Sampling; Sensitivity and Specificity; Sepsis; Small Business Innovation Research Grant; Specificity; Specimen; Speed; Surface; Symptoms; System; Testing; Time; TimeLine; Translating; Venous blood sampling; Whole Blood
Phase II
Contract Number: 2R44AI136064-02Start Date: 1/4/2018 Completed: 12/31/2021
Phase II year
2019(last award dollars: 2024)
Phase II Amount
$3,999,034Public Health Relevance Statement:
PROJECT NARRATIVE Infective Endocarditis (IE) is a serious and life-threatening disease and a significant economic burden due to prolonged intensive treatment. Early microbiological diagnosis is crucial to improving outcomes, but current standards employing blood cultures are lethargic and often yield false-negative results. This delay in crucial information prevents the administration of the evidence-based antimicrobial treatment precisely when it is maximally beneficial. HelixBind will address this problem and develop a novel turn-key approach for early microbiological IE-diagnosis. In this Phase II SBIR, we propose to further our Phase I feasibility work and develop the first fully-automated diagnostic capable of identifying the most prevalent pathogens causing IE, including those difficult or impossible to detect by standard methods, directly from phlebotomy specimens, without prior enrichment, reducing the diagnosis time from days or even weeks to just hours. The information provided would enable the clinician to apply an evidence-driven intervention from the onset of disease symptoms.
NIH Spending Category:
Cardiovascular; Clinical Research; Health Disparities; Heart Disease; Infectious Diseases; Minority Health; Rare Diseases
Project Terms:
Address; Adoption; Affect; American; Antibiotics; antimicrobial; assay development; Bacteria; base; Biological Assay; Blinded; Blood; Blood Circulation; Blood specimen; Clinical; Clinical Microbiology; Clinical Trials; Collaborations; Communicable Diseases; cost; cost effectiveness; Critical Care; cross reactivity; Detection; Development; Diagnosis; Diagnostic; diagnostic assay; Disease; Economic Burden; Endocarditis; Etiology; evidence base; Failure; Feedback; Fire - disasters; Freeze Drying; Funding; fungus; Hand; Heart; heart damage; High Prevalence; Hospitalization; Hospitals; Hour; Human; Impairment; improved; improved outcome; Indiana; Infection; Infective endocarditis; innovation; instrumentation; Intensive Care; internal control; Intervention; Laboratories; Left; Lesion; Lethargies; Life; Liquid substance; Medical center; medical schools; Memorial Sloan-Kettering Cancer Center; Methods; microbial; Microbiology; microorganism; Morbidity - disease rate; mortality; New England; novel; Onset of illness; Operative Surgical Procedures; Organism; Outcome; pathogen; Pathology; Patients; Performance; performance tests; Phase; Physicians; Pilot Projects; Plastics; prevent; Quality of life; Reagent; Resistance; resistance gene; resistant strain; Sampling; Sepsis; Septicemia; skin microbiota; Small Business Innovation Research Grant; Specificity; Specimen; Surface; Symptoms; System; Technology; Testing; Time; Translating; Universities; Venous blood sampling; verification and validation; Whole Blood; Work; Yeasts